(VIANEWS) – FARO Technologies (FARO), AbbVie (ABBV), Citi Trends (CTRN) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. FARO Technologies (FARO)

12.2% sales growth and 3.66% return on equity

FARO Technologies, Inc. designs, develops, manufactures, markets, and supports software driven three-dimensional (3D) measurement, imaging, and realization solutions worldwide.

FARO Technologies’s sales growth this year is expected to be 13.5% and 14.5% for next year.

Year-on-year quarterly revenue growth declined by 4%, now sitting on 300.58M for the twelve trailing months.

Volume

Today’s last reported volume for FARO Technologies is 4153 which is 94.33% below its average volume of 73287.

FARO Technologies’s sales growth is a negative 0% for the present quarter and 12.2% for the next. The company’s growth estimates for the ongoing quarter and the next is 175% and 54.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.66%.

Volatility

FARO Technologies’s last day, last week, and last month’s current volatility was 2.05%, 1.38%, and 1.36%, respectively.

FARO Technologies’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.41% (day), 2.76% (last week), and 2.59% (last month), respectively.

FARO Technologies’s Stock Yearly Top and Bottom Value

FARO Technologies’s stock is valued at $69.46 at 01:22 EST, way below its 52-week high of $97.88 and way above its 52-week low of $54.89.

FARO Technologies’s Moving Average

FARO Technologies’s value is under its 50-day moving average of $70.97 and way under its 200-day moving average of $79.31.

2. AbbVie (ABBV)

11.5% sales growth and 48.86% return on equity

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally.

AbbVie’s sales growth this year is anticipated to be 23.1% and 6.3% for next year.

Year-on-year quarterly revenue growth grew by 33.9%, now sitting on 53.73B for the twelve trailing months.

Volume

Today’s last reported volume for AbbVie is 4836160 which is 13.64% below its average volume of 5600500.

AbbVie’s sales growth for the next quarter is 11.5%. The company’s growth estimates for the ongoing quarter and the next is 32.1% and 14.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 48.86%.

Volatility

AbbVie’s last day, last week, and last month’s current volatility was 0.22%, 1.90%, and 1.04%, respectively.

AbbVie’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.63% (day), 4.06% (last week), and 2.10% (last month), respectively.

AbbVie’s Stock Yearly Top and Bottom Value

AbbVie’s stock is valued at $111.62 at 01:22 EST, under its 52-week high of $121.40 and way above its 52-week low of $79.11.

AbbVie’s Moving Average

AbbVie’s worth is under its 50-day moving average of $117.42 and below its 200-day moving average of $112.65.

Previous days news about AbbVie(ABBV)

  • According to Benzinga on Friday, 3 September, "Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates. "
  • According to Business Insider on Wednesday, 1 September, "Company’s key members came from multinational companies such as Novartis, AbbVie and Sanofi. "
  • According to Benzinga on Monday, 30 August, "Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. "

3. Citi Trends (CTRN)

8.7% sales growth and 52.06% return on equity

Citi Trends, Inc. operates as a value-priced retailer of fashion apparel, accessories, and home goods.

Citi Trends’s sales growth this year is anticipated to be 25.6% and 3.7% for next year.

Year-on-year quarterly revenue growth grew by 145.8%, now sitting on 952.55M for the twelve trailing months.

Volume

Today’s last reported volume for Citi Trends is 154077 which is 38.15% below its average volume of 249115.

Citi Trends’s sales growth for the next quarter is 8.7%. The company’s growth estimates for the present quarter and the next is a negative 0% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 52.06%.

Volatility

Citi Trends’s last day, last week, and last month’s current volatility was 2.70%, 3.62%, and 2.97%, respectively.

Citi Trends’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 7.20% (day), 7.14% (last week), and 5.54% (last month), respectively.

Citi Trends’s Stock Yearly Top and Bottom Value

Citi Trends’s stock is valued at $85.57 at 01:22 EST, way under its 52-week high of $111.44 and way higher than its 52-week low of $18.50.

Citi Trends’s Moving Average

Citi Trends’s value is above its 50-day moving average of $79.51 and below its 200-day moving average of $85.73.

4. ProLogis (PLD)

6.6% sales growth and 4.09% return on equity

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets.

ProLogis’s sales growth this year is expected to be 8.7% and 6.6% for next year.

Year-on-year quarterly revenue growth grew by 13.9%, now sitting on 4.88B for the twelve trailing months.

Volume

Today’s last reported volume for ProLogis is 2353710 which is 0.7% above its average volume of 2337240.

ProLogis’s sales growth for the next quarter is 6.6%. The company’s growth estimates for the current quarter and the next is 30% and 42.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.09%.

Volatility

ProLogis’s last day, last week, and last month’s current volatility was 0.49%, 1.18%, and 0.86%, respectively.

ProLogis’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.29% (day), 1.67% (last week), and 1.47% (last month), respectively.

ProLogis’s Stock Yearly Top and Bottom Value

ProLogis’s stock is valued at $138.99 at 01:22 EST, higher than its 52-week high of $128.87.

ProLogis’s Moving Average

ProLogis’s worth is way above its 50-day moving average of $123.97 and way above its 200-day moving average of $111.92.

LEAVE A REPLY

Please enter your comment!
Please enter your name here